Clinical trial · Observational
Study KBP-2020-CPHG Documenting New Cases of Primary Lung Cancer (PLC) Diagnosed in Respiratory Medicine Departments and Lung Cancer Units at General Hospitals From January 1st to December 31st 2020
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Twenty years after KBP-2000-CPHG study and ten years after KBP-2010-CPHG study, the CPHG proposes to conduct a new epidemiological study on primary PLC in order to evaluate and analyze the changes that have occurred over the last decade. Primary endpoint: Estimate 1-year- and 5-year-mortality rates in patients with PLC. Secondary endpoints: * Describe PLC patient population managed by pulmonologists at French General Hospitals in 2020 * Describe PLC diagnostic and therapeutic management by pulmonologists at French General Hospitals in 2020 and compare them to KBP-2000-CPHG and KBP-2010-CPHG studies * Estimate prognostic factors * Compare patient and tumor characteristics to those observed for KBP-2010-CPHG and KBP-2000-CPHG studies * Compare observed survival rates to those reported for KBP-2000-CPHG and KBP-2010-CPHG studies
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Estimate 1-year mortality rates in patients with PLC.
- timeFrame
- 1 year
- description
- Global survival at 1 year
- measure
- Estimate 5-year mortality rates in patients with PLC.
- timeFrame
- 5 years
- description
- Global survival at 5 years
Secondary outcomes (2)
- measure
- Describe PLC patient population managed by pulmonologists at French General Hospitals in 2020
- timeFrame
- 1 year
- description
- \- Patient data: age, gender, birth location, height, weight, comorbidity score, smoking status, cannabis uptake, Performance Status, and death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Primary Lung Cancer histologically (or cytologically or presence of a mutation on liquid biopsy with compatible imaging) proven between January 1st and December 31st, 2020\* * Follow-up by a lung specialist at a General Hospital * Oral informed consent \* date of collected sample Exclusion Criteria: * Age \< 18 years * Secondary lung cancer * Recurrence of same histological type PLC- left to the investigator discretion according to the clinic and the imagery * Previous enrolment in the study * Freedom deprived patient following a legal or administrative decision * Patient unable to give his(her) consent
References
Publications (1)
- DERIVEDDebieuvre D, Falchero L, Molinier O, Couraud S, Cortot A, Meyer N, Asselain B, Auvray E, Templement-Grangerat D, Bizieux A, Tredaniel J, Schneider S, Auliac JB, Bylicki O, Letierce A, Morel H. Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020. NEJM Evid. 2025 Jul;4(7):EVIDoa2400443. doi: 10.1056/EVIDoa2400443. Epub 2025 Jun 24. PMID 40552964